Literature DB >> 20224432

A comparative study on inter and intralaboratory reproducibility of renin measurement with a conventional enzymatic method and a new chemiluminescent assay of immunoreactive renin.

Alberto Morganti1.   

Abstract

BACKGROUND: The activity of the renin-angiotensin system is usually evaluated as plasma renin activity (PRA, ngAI/ml per h) but the reproducibility of this enzymatic assay is notoriously scarce. We compared the inter and intralaboratory reproducibilities of PRA with those of a new automated chemiluminescent assay, which allows the direct quantification of immunoreactive renin [chemiluminescent immunoreactive renin (CLIR), microU/ml].
METHODS: Aliquots from six pool plasmas of patients with very low to very high PRA levels were measured in 12 centres with both the enzymatic and the direct assays. The same methods were applied to three control plasma preparations with known renin content.
RESULTS: In pool plasmas, mean PRA values ranged from 0.14 +/- 0.08 to 18.9 +/- 4.1 ngAI/ml per h, whereas those of CLIR ranged from 4.2 +/- 1.7 to 436 +/- 47 microU/ml. In control plasmas, mean values of PRA and of CLIR were always within the expected range. Overall, there was a significant correlation between the two methods (r = 0.73, P < 0.01). Similar correlations were found in plasmas subdivided in those with low, intermediate and high PRA. However, the coefficients of variation among laboratories found for PRA were always higher than those of CLIR, ranging from 59.4 to 17.1% for PRA, and from 41.0 to 10.7% for CLIR (P < 0.01). Also, the mean intralaboratory variability was higher for PRA than for CLIR, being respectively, 8.5 and 4.5% (P < 0.01).
CONCLUSION: The measurement of renin with the chemiluminescent method is a reliable alternative to PRA, having the advantage of a superior inter and intralaboratory reproducibility.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20224432     DOI: 10.1097/HJH.0b013e32833857ad

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  11 in total

1.  Acute administration of acyl, but not desacyl ghrelin, decreases blood pressure in healthy humans.

Authors:  Cecilia J Zhang; Martin Bidlingmaier; Mekibib Altaye; Laura C Page; David D'Alessio; Matthias H Tschöp; Jenny Tong
Journal:  Eur J Endocrinol       Date:  2016-11-09       Impact factor: 6.664

2.  Clinical management of renovascular hypertension: practical recommendations from the Italian Society of Hypertension (SIIA).

Authors:  Chiara Lonati; Alberto Morganti
Journal:  High Blood Press Cardiovasc Prev       Date:  2013-09-11

3.  Active renin mass concentration to determine aldosterone-to-renin ratio in screening for primary aldosteronism.

Authors:  François Corbin; Pierre Douville; Marcel Lebel
Journal:  Int J Nephrol Renovasc Dis       Date:  2011-07-28

4.  Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial.

Authors:  Morris J Brown; Bryan Williams; Steve V Morant; David J Webb; Mark J Caulfield; J Kennedy Cruickshank; Ian Ford; Gordon McInnes; Peter Sever; Jackie Salsbury; Isla S Mackenzie; Sandosh Padmanabhan; Thomas M MacDonald
Journal:  Lancet Diabetes Endocrinol       Date:  2015-10-18       Impact factor: 32.069

5.  Aldosterone/direct renin concentration ratio as a screening test for primary aldosteronism: A meta-analysis.

Authors:  Xiyue Li; Richa Goswami; Shumin Yang; Qifu Li
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2016-08-17       Impact factor: 1.636

6.  Establishing a novel assay system for measuring renin concentration using cost effective recombinant ovine angiotensinogen.

Authors:  Jobaida Akther; A H M Nurun Nabi; Satoshi Ohno; Takashi Yokogawa; Tsutomu Nakagawa; Fumiaki Suzuki; Akio Ebihara
Journal:  Heliyon       Date:  2019-04-04

7.  Clinical determinants and prognostic implications of renin and aldosterone in patients with symptomatic heart failure.

Authors:  Masatake Kobayashi; Susan Stienen; Jozine M Ter Maaten; Kenneth Dickstein; Nilesh J Samani; Chim C Lang; Leong L Ng; Stefan D Anker; Macro Metra; Gregoire Preud'homme; Kevin Duarte; Zohra Lamiral; Nicolas Girerd; Patrick Rossignol; Dirk J van Veldhuisen; Adriaan A Voors; Faiez Zannad; João Pedro Ferreira
Journal:  ESC Heart Fail       Date:  2020-03-13

8.  Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.

Authors:  Bryan Williams; Thomas M MacDonald; Steve Morant; David J Webb; Peter Sever; Gordon McInnes; Ian Ford; J Kennedy Cruickshank; Mark J Caulfield; Jackie Salsbury; Isla Mackenzie; Sandosh Padmanabhan; Morris J Brown
Journal:  Lancet       Date:  2015-09-20       Impact factor: 79.321

9.  Combination Therapy Is Superior to Sequential Monotherapy for the Initial Treatment of Hypertension: A Double-Blind Randomized Controlled Trial.

Authors:  Thomas M MacDonald; Bryan Williams; David J Webb; Steve Morant; Mark Caulfield; J Kennedy Cruickshank; Ian Ford; Peter Sever; Isla S Mackenzie; Sandosh Padmanabhan; Gerald P McCann; Jackie Salsbury; Gordon McInnes; Morris J Brown
Journal:  J Am Heart Assoc       Date:  2017-11-18       Impact factor: 5.501

10.  Renin profiling predicts neurohormonal response to sacubitril/valsartan.

Authors:  Giuseppe Vergaro; Paolo Sciarrone; Concetta Prontera; Silvia Masotti; Veronica Musetti; Alessandro Valleggi; Alberto Giannoni; Michele Senni; Michele Emdin; Claudio Passino
Journal:  ESC Heart Fail       Date:  2020-11-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.